Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in type 2 diabetes mellitus with psoriasis
ChiCTR1800015296Phase 4Recruiting
- Sponsor
- 900th Hospital of Joint Logistics Support Force of PLA
- Start
- Apr 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liraglutide in type 2 diabetes mellitus (T2DM) and psoriasis, sponsored by 900th Hospital of Joint Logistics Support Force of PLA. Primary endpoints: Psoriasis Area and Severity Index, Serum inflammatory factors IL-17, IL-22, IL-23, and TNF-a and 3 more. Started Apr 2018; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)psoriasis
Beyond the preview
Go deeper on ChiCTR1800015296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015296.